Ad
related to: what is sickle cell disease people- Learn About Treatment
Learn About the Treatment Journey.
Watch the Video to Learn More.
- Safety and Side Effects
Review the Important Safety
Information & Side Effects.
- View Discussion Guides
Download Treatment Brochures,
Discussion Guides, and More.
- Patient Information
View Important Patient Information.
Understand the Treatment.
- Patient FAQs
Get Answers to Common Questions.
Understand the Potential Risks.
- Find an ATC
Find an Authorized Treatment Center
On the Official Patient Website.
- Learn About Treatment
Search results
Results From The WOW.Com Content Network
Sickle cell disease affects an estimated 100,000 people in the U.S., most of whom are Black. The withdrawal is the latest headwind for Pfizer and its CEO Albert Bourla.
Sickle cell disease (SCD), also simply called sickle cell, is a group of hemoglobin-related blood disorders typically inherited. [2] The most common type is known as sickle cell anemia. [2] It results in an abnormality in the oxygen-carrying protein haemoglobin found in red blood cells. [2] This leads to a rigid, sickle -like shape under ...
Pfizer bought Oxbryta, also known as voxelotor, as part of its $5.4 billion buyout of Global Blood Therapeutics in 2022. Pfizer is also discontinuing all studies and access programs related to the ...
One example she cites is the health care industry’s handling of sickle cell anemia, which 1 in 13 Black babies in the U.S. are born with, according to the Centers for Disease Control and Prevention.
Vivek Ganapathy Ramaswamy (/ v ɪ ˈ v eɪ k r ɑː m ə ˈ s w ɑː m iː /; [1] [2] vih-VAYK rah-mə-SWAH-mee; born August 9, 1985) is an American entrepreneur.He founded Roivant Sciences, a pharmaceutical company, in 2014.
Anemia or anaemia (British English) is a blood disorder in which the blood has a reduced ability to carry oxygen. This can be due to a lower than normal number of red blood cells, a reduction in the amount of hemoglobin available for oxygen transport, or abnormalities in hemoglobin that impair its function. [3][4]
In December 2023, the FDA approved the first gene therapy in the US to treat patients with Sickle Cell Disease (SCD). The FDA approved two milestone treatments, Casgevy and Lyfgenia, representing the first cell-based gene therapies for the treatment of SCD.
Sickle-cell versions of hemoglobin stick to themselves, stacking to form fibers that distort the shape of red blood cells carrying the protein. These sickle-shaped cells no longer flow smoothly through blood vessels, having a tendency to clog or degrade, causing the medical problems associated with this disease. [citation needed]
Ad
related to: what is sickle cell disease people